Cargando…
Cysteamine bitartrate delayed‐release capsules control leukocyte cystine levels and promote statural growth and kidney health in an open‐label study of treatment‐naïve patients <6 years of age with nephropathic cystinosis
Nephropathic cystinosis is a rare autosomal recessive lysosomal storage disease that is characterized by accumulation of cysteine and formation of crystals within cells of different organs and tissues causing systemic manifestations in childhood that include poor linear growth, ocular involvement, h...
Autores principales: | Vaisbich, Maria Helena, Caires Ferreira, Juliana, Price, Heather, Young, Kyleen D., Sile, Saba, Checani, Gregg, Langman, Craig B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743345/ https://www.ncbi.nlm.nih.gov/pubmed/35028272 http://dx.doi.org/10.1002/jmd2.12260 |
Ejemplares similares
-
Long-term clinical benefits of delayed-release cysteamine bitartrate capsules in patients with nephropathic cystinosis (response to “A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis”)
por: Langman, Craig B.
Publicado: (2023) -
Quality of Life is Improved and Kidney Function Preserved in Patients with Nephropathic Cystinosis Treated for 2 Years with Delayed-Release Cysteamine Bitartrate
por: Langman, Craig B., et al.
Publicado: (2014) -
Enteric-Coated Cysteamine Bitartrate in Cystinosis Patients
por: Klank, Sabrina, et al.
Publicado: (2023) -
A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis
por: Armas, Danielle, et al.
Publicado: (2018) -
Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients
por: Bouazza, Naïm, et al.
Publicado: (2011)